Right to Try Laws and the FDA - By Dr Nicola Davies

12 March 2018

Right to Try laws give terminally ill patients access to therapies that have passed Phase I testing but have not achieved US Food and Drug Administration approval. The FDA’s current program, expanded access, already gives these patients access to experimental drugs, but Right to Try laws expedite the process and reduce the FDA’s role in it, comments Dr Nicola Davies in her monthly FDA blog for The Pharma Letter.

38 out of 50 US states have passed various versions of Right to Try laws, and President Donald Trump has voiced support for the federal Right to Try bill passed by the Senate in 2017. Despite wide public support for the federal bill, many, including the FDA, oppose it.

Thalidomide: The Drug that Started It All

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK